Tiratricol is a medication used to treat children with a rare genetic condition called MCT8 deficiency, which affects thyroid hormone transport. This medication is designed to help improve neurodevelopment, particularly focusing on motor skills and movement abilities in young patients. It works by mimicking thyroid hormones and can reach areas of the body where natural thyroid hormones cannot be properly transported due to the genetic defect.

Monocarboxylate Transporter 8 (MCT8) Deficiency – A rare genetic condition that affects the body’s ability to transport thyroid hormones into cells, particularly in the brain. The condition primarily affects males and becomes apparent in early infancy or early childhood. It is characterized by problems with movement, muscle control, and developmental delays. Children with MCT8 deficiency typically have difficulty with physical activities like holding up their head, sitting, crawling, and walking. The condition also impacts intellectual development and speech abilities. This disorder is caused by mutations in the SLC16A2 gene, which provides instructions for making the MCT8 protein.